Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds

PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq:AGRX) (“Agile Therapeutics” or the “Company”), a women’s healthcare company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per share, at a reduced exercise price of $1.25 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-271249 and 333-264960) and Form S-1MEF (File No. 333-265959). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.8 million, prior to deducting placement agent fees and estimated offering expenses.

Read more at globenewswire.com